Möchten Sie immer auf dem neuesten Stand bleiben?

Navacaprant did not achieve the primary endpoint in KOASTAL-2 or -3; Company to discontinue development of navacaprant Advancing potential best-in-class programs with NMRA-511 in Alzheimer’s disease...

Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH New...

ATI Engage® Series, a product by ATI Nursing Education, is the winner of the Digital Learning Innovation Award in the 8th annual EdTech Breakthrough Awards

High objective response rate of 92.9% in second line patients who have progressed on a BTK inhibitor and have not received BCL2 inhibitor treatment Updated Phase 1a data further supports a median...

Additional funding will extend anticipated runway into second quarter of 2027 Strategic priority is to establish a partnership to advance neflamapimod into Phase 3 in dementia with Lewy bodies ...

KT-579 demonstrated consistent disease-modifying activity comparable or superior to approved and clinically active therapies in multiple preclinical lupus models  KT-579 Phase 1 healthy volunteer...

Potentially best-in-mechanism immunogenicity profile, with only 3.7% of participants developing antidrug antibodies Complete blockade of TL1A binding to DR3 for over 3 months expected at doses of 1...

- Registrational expansion cohort enrolled 71 participants; topline data planned for Q1 2027 -  WALTHAM, Mass., June 03, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a...

An independent safety Data Monitoring Committee recommends the initiation of Cohort 2 in Entrada Therapeutics’ ELEVATE-45-201 study.

Hyderabad, India, June 02, 2026 (GLOBE NEWSWIRE) -- According to Mordor Intelligence, the global black mass recycling market size is experiencing strong growth, with its value expected to rise...